NWBO will require U.S. approval to generate meaningful revenue. MHRA may approve the drug but most new oncology drugs don't get reimbursement by NICE and therefore get very little revenue from U.K.
Sawston approval is meaningful for LP to help Advent to sell their services to any biotech. But without any approval, manufacturing capability is worthless. And if MHRA gives them approval, but NICE won't pay, they will do very little business.
For any drug company, U.S. pays for the majority of their revenue and profits (and stock price benefits).
Market Data 
Markets 
AI
